Skip to main content

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Web Exclusives - FDA Approvals

On August 5, 2022, the FDA accelerated the approval of darolutamide (Nubeqa; Bayer Healthcare), an androgen receptor inhibitor, in combination with docetaxel, for the treatment of metastatic hormone-sensitive prostate cancer in adults.

Darolutamide was previously approved for nonmetastatic castration-resistant prostate cancer.

The approval of this new indication was based on results of the randomized, multicenter, double-blind, placebo-controlled ARASENS phase 3 clinical trial of 1306 patients with metastatic hormone-sensitive prostate cancer. The patients received 600 mg of darolutamide orally twice daily plus 75 mg/m2 of docetaxel intravenously every 3 weeks for up to 6 cycles or docetaxel plus placebo.

The main end point was overall survival (OS); the secondary end point was time to pain progression. The median OS was not reached in the darolutamide arm versus 48.9 months (95% confidence interval [CI], 44.4-not reached) in the placebo arm (95% CI, 0.57-0.80; P <.0001).

Related Items
Directory of FDA Approvals, August Through December 2023
December 2023 Vol 16, Payers' Guide to FDA Updates published on January 26, 2024 in FDA Approvals
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Ogsiveo First Treatment FDA Approved for Desmoid Tumors
Web Exclusives published on January 2, 2024 in FDA Approvals
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 18, 2023 in FDA Approvals
Last modified: December 20, 2022